AllAnalyst Report
Morningstar•September 25, 2020
Morningstar•September 25, 2020Merck & Co., Inc.: President Trump’s Updated Healthcare Policy Targets Drug Costs, but Implementation Looks Tough
Summary
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiovascular disease, asthma, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally,
Subscribe to Yahoo Finance Plus Essential for full access
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
Actions
Download Full ReportRelated Reports
- Analyst Report: Exxon Mobil CorporationApr 19, 2024 •
XOM
- Analyst Report: The Procter & Gamble CompanyApr 19, 2024 •
PG
- Technical Assessment: Neutral in the Intermediate-TermApr 19, 2024 •
AA, LLY
- Analyst Report: The Boeing CompanyApr 18, 2024 •
BA
- Analyst Report: Johnson & JohnsonApr 18, 2024 •
JNJ
Analyst Profile
Damien Conover
Sector DirectorDamien Conover, CFA, is director of healthcare equity research for Morningstar Research Services LLC, a wholly owned subsidiary of Morningstar, Inc. He is also director of equity strategy, responsible for helping to shape, package, and surface research based on Morningstar's investment philosophy by working closely with the firm's North American sector strategists and directors.Before joining Morningstar in 2007, Conover was an equity research analyst covering the healthcare sector for Raymond James, Bank of Montreal, and Tucker Anthony.Conover holds bachelor's and master's degrees in finance from the University of Wisconsin and was a member of its Applied Security Analysis Program. He also holds the Chartered Financial Analyst® designation.